Leerink Partnrs Has Positive Forecast for KYMR Q3 Earnings

Key Points

• Investment analysts at Leerink Partners have raised their Q3 2025 earnings estimates for Kymera Therapeutics, increasing their forecast from ($1.12) to ($0.96) per share.
• Multiple analysts have issued reports on the stock, with Goldman Sachs upgrading Kymera to a "strong buy" and setting varying price targets between $53.00 and $72.00 across other firms.
• Kymera's stock experienced a slight increase of 2.2% and currently trades at $40.73, with a twelve-month high of $53.27 and a low of $19.44.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities research analysts at Leerink Partnrs increased their Q3 2025 earnings per share estimates for shares of Kymera Therapeutics in a research note issued on Monday, August 11th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.96) per share for the quarter, up from their prior forecast of ($1.12). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.73) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($0.97) EPS and FY2026 earnings at ($4.12) EPS.

A number of other research firms have also commented on KYMR. BTIG Research reiterated a "buy" rating and issued a $59.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 26th. UBS Group reduced their price target on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. JPMorgan Chase & Co. upped their price target on Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, June 3rd. Morgan Stanley started coverage on Kymera Therapeutics in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $70.00 price target on the stock. Finally, Wells Fargo & Company reduced their price target on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating on the stock in a research report on Thursday, June 26th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of "Buy" and a consensus target price of $59.11.

Kymera Therapeutics Stock Down 1.4%

Shares of NASDAQ KYMR traded down $0.6150 during trading on Thursday, reaching $43.0050. The company had a trading volume of 213,965 shares, compared to its average volume of 746,282. The company's fifty day moving average price is $44.57 and its 200-day moving average price is $36.47. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $53.27. The stock has a market cap of $3.07 billion, a P/E ratio of -12.39 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The firm had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. During the same quarter in the prior year, the firm earned ($0.58) EPS. The company's revenue was down 55.1% on a year-over-year basis.

Insider Activity at Kymera Therapeutics

In other news, Director Bvf Partners L. P/Il purchased 317,167 shares of the company's stock in a transaction that occurred on Monday, June 30th. The shares were acquired at an average cost of $44.00 per share, with a total value of $13,955,348.00. Following the purchase, the director owned 2,798,795 shares in the company, valued at $123,146,980. This represents a 12.78% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the transaction, the chief executive officer directly owned 660,482 shares in the company, valued at approximately $32,363,618. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,349 shares of company stock worth $2,334,301 over the last quarter. 16.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KYMR. Farther Finance Advisors LLC raised its stake in Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after buying an additional 540 shares during the period. PNC Financial Services Group Inc. raised its stake in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after buying an additional 770 shares during the period. State of Wyoming purchased a new stake in shares of Kymera Therapeutics in the fourth quarter worth approximately $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics in the fourth quarter worth approximately $55,000. Finally, KBC Group NV raised its stake in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after purchasing an additional 328 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.